Comparative Analysis of Different Tests to Evaluate Prognosis of Patients on Liver Transplant Waiting List

Overview

It is a cohort to evaluate the power of different diagnostic tests in predicting the prognosis of patients with severe liver disease. Patients with decompensated liver cirrhosis on the waiting list for liver transplantation will be evaluated with comparison of different diagnostic tests according to the MELD score (Model for End-Stage Liver Disease), MELD-Na (Model for End-Stage Liver Disease and sodium), indocyanine green clearance test, hepatic venous pressure gradient and transient elastography. All patients will be submitted to all the tests and prospectively followed for 6 months, to establish mortality and complications related to liver disease in order to define the value of each method to predict outcomes.

Full Title of Study: “Comparative Analysis of Indocyanine Green Clearance Test, MELD Score, MELD-Na Score, Transient Elastography and Hepatic Venous Pressure Gradient to Evaluate Prognosis of Patients on Liver Transplant Waiting List”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: November 2018

Arms, Groups and Cohorts

  • Patients with advanced liver disease
    • Inclusion criteria are diagnosis of cirrhosis with portal hypertension detected by abdominal ultrasound with color Doppler flowmetry or upper digestive endoscopy. Exclusion criteria were age 18 or older, previous contrast allergy, hepatocellular carcinoma or any malignancy except basocellular carcinoma, renal failure (creatinine level >1.5 mg/dL), severe bleeding disorder (prothrombin activity test < 30% or platelets count <35,000/mcL) or decompensated cirrhosis characterized by severe ascites or grade II or higher encephalopathy. Patients with alcoholic cirrhosis should be abstinent for at least six months.

Clinical Trial Outcome Measures

Primary Measures

  • All cause mortality
    • Time Frame: 6 months
    • Mortality within 6 months after evaluation, classifying as related or non-related to liver disease

Secondary Measures

  • Chronic liver failure and portal hypertension complications
    • Time Frame: 6 months
    • Complications: gastroesophageal variceal bleeding worsening of hepatic encephalopathy decompensated ascites and spontaneous bacterial peritonitis hepatorenal syndrome

Participating in This Clinical Trial

Inclusion Criteria

  • the study includes patients (80 patients) – were male and female – aged between 18 and 69 years with chronic liver disease – with MELD inclusion greater than or equal to 14 to 30 Exclusion Criteria:

  • they have been transplanted – have a diagnosis of primary malignant liver (HCC) signed by imaging tests performed – MELD scores greater than 30.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 69 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Guilherme Rezende
  • Collaborator
    • Rio de Janeiro State Research Supporting Foundation (FAPERJ)
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Guilherme Rezende, Associate Professor, MD PhD – Universidade Federal do Rio de Janeiro
  • Overall Official(s)
    • Guilherme FM Rezende, MD PhD, Study Chair, Universidade Federal do Rio de Janeiro

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.